The future of long-acting agents for preexposure prophylaxis

Purpose of review The main reason for the failure of oral preexposure prophylaxis (PrEP) regimens for HIV is poor adherence. Intramuscular cabotegravir was recently approved for PrEP, and a number of other long-acting antiretroviral formulations and products are currently in clinical development. This includes subcutaneous and intravenous injections, implants, and microarray (microneedle) patches, as well as extended duration oral drugs. The success and future uptake of these products will depend on a variety of factors. Recent findings Long-acting delivery of antiretroviral agents for PrEP confers significant advantages over short-acting oral delivery. This is exemplified by the superior efficacy of intramuscular cabotegravir given every eight weeks as compared to daily oral co-formulated tenofovir disoproxil fumarate and emtricitabine. There is also evidence for PrEP efficacy for a broadly neutralizing monoclonal antibody given intravenously every eight weeks. One of the leading candidates for long-acting PrEP, islatravir, was being studied as a monthly oral drug or a nonerodable subcutaneous implant inserted for up to 12 months. However, clinical studies of this agent were put on hold in late 2021 because of unanticipated lymphopenia. Summary Long-acting antiretroviral products have substantial promise for PrEP and have particular advantages over daily oral drugs based mainly on improved adherence. However, there are barriers to further uptake that include the need for more intensive interaction with systems of healthcare delivery, greater expense and complexity of implementation, and unexpected long-term toxicities.

[1]  H. Dvory‐Sobol,et al.  Lenacapavir: a first-in-class HIV-1 capsid inhibitor. , 2022, Current opinion in HIV and AIDS.

[2]  M. Baum,et al.  Drug-releasing vaginal rings for HIV/STI and pregnancy prevention: a review of recent advances and clinical applications , 2021, Expert opinion on drug delivery.

[3]  R. Donnelly,et al.  Nanoemulsion-based dissolving microneedle arrays for enhanced intradermal and transdermal delivery , 2021, Drug Delivery and Translational Research.

[4]  A. Goodey,et al.  Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial , 2021, Nature Medicine.

[5]  H. Gendelman,et al.  Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles , 2021, Nature Communications.

[6]  R. Mogg,et al.  Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV , 2021, Clinical and translational science.

[7]  T. Holtz,et al.  Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. , 2021, The New England journal of medicine.

[8]  A. van der Straten,et al.  Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting , 2021, AIDS research and human retroviruses.

[9]  C. Petropoulos,et al.  Characterization of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. , 2021, The Journal of infectious diseases.

[10]  Allan C. deCamp,et al.  Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. , 2021, The New England journal of medicine.

[11]  H. Gendelman,et al.  Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir , 2021, Nature Communications.

[12]  C. Flexner,et al.  LONG-ACTING DRUGS AND FORMULATIONS FOR THE TREATMENT AND PREVENTION OF HIV. , 2020, International journal of antimicrobial agents.

[13]  K. Ruxrungtham,et al.  Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection , 2020, Expert opinion on drug metabolism & toxicology.

[14]  C. Flexner,et al.  Long-acting implants to treat and prevent HIV infection. , 2019, Current opinion in HIV and AIDS.

[15]  C. Flexner,et al.  Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[16]  J. Mascola,et al.  Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. , 2019, The lancet. HIV.

[17]  C. Flexner,et al.  Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities , 2019, The lancet. HIV.

[18]  C. Flexner,et al.  Predicting Drug–Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling , 2019, The Journal of infectious diseases.

[19]  Md. Sohel Rana,et al.  Interest of Youth Living With HIV in Long-Acting Antiretrovirals , 2019, Journal of acquired immune deficiency syndromes.

[20]  Ryan F. Donnelly,et al.  Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[21]  R. Mumper,et al.  Ultra-long-acting removable drug delivery system for HIV treatment and prevention , 2018, Nature Communications.

[22]  E. Egelund,et al.  Tenofovir Alafenamide for the Treatment of Chronic Hepatitis B Monoinfection , 2018, Pharmacotherapy.

[23]  S. Sarafianos,et al.  4′-Ethynyl-2-fluoro-2′-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor , 2018, Current opinion in HIV and AIDS.

[24]  M. Caskey,et al.  Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection , 2018, Current opinion in HIV and AIDS.

[25]  C. Flexner,et al.  Harnessing nanostructured systems for improved treatment and prevention of HIV disease , 2018, Bioengineering & translational medicine.

[26]  R. Jacobstein Liftoff: The Blossoming of Contraceptive Implant Use in Africa , 2018, Global Health: Science and Practice.

[27]  M. Wainberg,et al.  M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA , 2017, The Journal of antimicrobial chemotherapy.

[28]  G. Learn,et al.  Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. , 2016, The New England journal of medicine.

[29]  Thomas J. Smith,et al.  Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis , 2015, Antimicrobial Agents and Chemotherapy.

[30]  D. Hazuda,et al.  Derivatives of Mesoxalic Acid Block Translocation of HIV-1 Reverse Transcriptase* , 2014, The Journal of Biological Chemistry.

[31]  U. Bredeek,et al.  Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults , 2013, Journal of acquired immune deficiency syndromes.

[32]  Steven R Tannenbaum,et al.  Biphasic Elimination of Tenofovir Diphosphate and Nonlinear Pharmacokinetics of Zidovudine Triphosphate in a Microdosing Study , 2012, Journal of acquired immune deficiency syndromes.

[33]  C. Atwood,et al.  Leuprolide acetate: a drug of diverse clinical applications , 2007, Expert opinion on investigational drugs.